More Information: Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Mission and Goals

IPOP is a state-of-the-art program dedicated to translational immuno-oncology research, discovery, and collaboration. Our mission is to partner with MSK investigators and industry. IPOP emphasizes large-scale immunogenomics capabilities in partnership with scientists and companies running clinical trials to foster immuno-oncology discovery and drug development. The specific goals of the platform are:

  • engaging in flagship projects with investigators from MSK and other New York-area institutions
  • facilitating more industry contracts and collaborations and enhancing capabilities
  • facilitating more collaborative work on national clinical trials
  • enhancing experimental and analytical capabilities for immunogenomics and large-scale, data-rich immunology studies
  • driving MSK’s intellectual property engine in immuno-oncology
  • developing immuno-oncology–driven diagnostics in partnership with clinical (CLIA-certified) labs at MSK
  • establishing an experimental and analytical engine to tackle the complexity of immunogenomics:
    • cBIO Portal for Immunotherapy: a searchable, minable portal for major genomic, transcriptomic, and high-dimensional immunologic datasets for patients from all over the world treated with immuno-oncology therapeutics, facilitating analysis of features relevant to immuno-oncology, with application-driven access for the research and clinical trials community
    • high-throughput cancer antigen screening platform
    • open-source T cell receptor repertoire sequencing @ MSK: high-throughput processing with Integrated Genomics Operation; analysis portal and end-user data availability
    • flagship precision immuno-oncology projects: industry contracts for innovative clinical trials; precision immunotherapy for kidney cancer and head and neck tumors